Waldenstrom Macroglobulinemia — Trials

Waldenstrom Macroglobulinemia — Trials · CancerIndex

Clinical trials

Registered studies

308 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 59
Recruiting: 26
Ph III recruiting: 2
Growth YoY: —
Industry share: 39%
Top sponsor: Christian Buske
Termination share: 30.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02844309	The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM(BDH-WM02)	completed	Phase 4	44	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	1	Feb 11, 2026	clinicaltrials
NCT02844322	The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia(BDH-WM01)	completed	Phase 4	35	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER